UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET

Company Participants

Vincent Perrone - Head of IR
Elizabeth Barrett - President & CEO
Mark Schoenberg - Chief Medical Officer
Don Kim - CFO
Jeff Bova - Chief Commercial Officer

Conference Call Participants

Tara Bancroft - TD Cowen
Raghuram Selvaraju - H.C. Wainwright & Co
Matt Kaplan - Ladenburg Thalmann
Leland Gershell - Oppenheimer

Operator

Good morning ladies and gentlemen. Thank you for standing by. Welcome to the UroGen Pharma First Quarter 2024 Earnings Call. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Vincent Perrone, Head of Investor Relations. You may begin.

Vincent Perrone

Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's First Quarter 2024 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our corporate highlights and financial results for the quarter ended March 31, 2024. The press release can be accessed on the Investors portion of our website.

Joining me today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to JELMYTO, our ongoing and planned clinical trials, commercial and clinical milestones, market and revenue opportunities, our commercialization strategy and expectation, as well as potential future commercialization activities for UGN-102 if approved. Anticipated data including ENVISION durability data, regulatory filings and decisions, including UGN-102 potentially receiving priority review, UGN-102 being the primary growth driver for UroGen if approved, future R&D efforts, our corporate goals and 2024 financial guidance among other things.

These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements and UroGen disclaims any obligations to update these statements.

With that, I'll turn the call over to Liz. Liz?

Elizabeth Barrett

Thank you, Vincent, and thank you, everyone, for joining us this morning. As we look ahead to 2024, we have several near-term catalysts, including the planned release of the 12-month duration of response data from the ENVISION study in June, with our expected NDA submission this year.